Internship
Cardiosense
11-50 employees
Non-invasive cardiac monitoring platform using AI
No salary listed
Chicago, IL, USA
Upload your resume to see how it matches 16 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
- Bachelors in Electrical Engineering, Computer Science, Statistics, Mathematics, or related fields. Master’s or PhD student/graduate preferred.
- 2+ years of experience in the field of data science or machine learning with a focus on biomedical applications.
- Expertise in programming languages such as Python, R, or Scala.
- Exposure to machine learning frameworks (TensorFlow, PyTorch, Scikit-learn).
- Strong analytical thinking and problem-solving abilities.
- Excellent communication and presentation skills.
- Proven ability to influence cross-functional teams and stakeholders.
- Collaborate with cross-functional teams to identify opportunities for leveraging company data to develop machine learning solutions.
- Collaborate with clinical teams and external vendors to facilitate data collection.
- Design, develop, and deploy scalable machine learning models and advanced analytics.
- Apply digital signal processing techniques to physiological waveforms (PPG, ECG, SCG, etc.) and build novel machine learning algorithms for hemodynamic assessment.
- Optimize existing algorithms and pipelines to improve efficiency and performance.
- Perform exploratory data analysis to extract actionable insights.
- Develop predictive, prescriptive, and descriptive analytics to inform decision-making.
- Work with structured and unstructured data to uncover trends and patterns.
- Partner with data engineering teams to ensure the availability of robust data pipelines.
- Recommend and implement data tools, frameworks, and platforms to enhance workflows.
- Communicate findings and recommendations to technical and non-technical stakeholders.
- Master’s or PhD student/graduate preferred.
Cardiosense is focused on improving cardiac care through a non-invasive monitoring platform that uses biometric sensors and artificial intelligence (AI) to analyze heart activity. The platform captures the electromechanical behavior of each heartbeat, allowing for early detection of heart function decline. This enables healthcare providers to identify at-risk patients and take proactive measures to prevent serious cardiac issues. Unlike traditional methods that require invasive procedures, Cardiosense's solution is safer and easier for continuous patient monitoring. The company targets hospitals and clinics, generating revenue through the sale of wearable devices and subscription services for its analytics platform. The goal is to provide actionable insights that enhance patient care and improve recovery outcomes, with the technology currently in investigational use.
Company Size
11-50
Company Stage
Series A
Total Funding
$15.1M
Headquarters
Chicago, Illinois
Founded
2020
Simplify's Take
What believers are saying
- Cardiosense raised $15.1M in Series A funding to accelerate product development.
- The global cardiac monitoring market is projected to grow at a 7.5% CAGR until 2030.
- Recent FDA approvals of AI tools suggest a favorable regulatory environment for Cardiosense.
What critics are saying
- Increased competition from Apple and Fitbit could threaten Cardiosense's market share.
- Regulatory hurdles may delay broader market entry and expansion for Cardiosense.
- Continuous funding is needed for R&D, posing financial risks if future rounds fail.
What makes Cardiosense unique
- Cardiosense offers a non-invasive cardiac monitoring platform using AI and biometric sensors.
- Their platform detects early signs of cardiac decline before symptoms appear.
- Cardiosense's technology provides actionable insights for personalized patient care.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Relocation Assistance
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 14%Cardiosense Receives $15.1M Series A Round Back to HomeCHICAGO, IL, Cardiosense announced that it has raised $15.1 million in Series A funding.Cardiosense, a digital health company leveraging artificial intelligence and multi-sensor devices to enable early detection of cardiovascular disease, announced today that it has raised $15.1 million in Series A funding, co-led by Broadview Ventures and Hatteras Venture Partners, with participation from Laerdal Million Lives Fund, OSF Ventures, UnityPoint Health Ventures, and Portal Innovations. The capital will be used to support team expansion, accelerate product development, and fund an expansive heart failure study.Cardiosense is building a physiological waveform AI platform to develop predictive biomarkers to detect and manage cardiac disease. The Company has developed a suite of novel digital tools, multi-sensor devices, and analysis algorithms to detect early signs of cardiovascular disease, inform personalized therapy, and improve patient outcomes.(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page